| 1 |
Song Q, Ding X, Liu Y, Liu W, Li J, Wang B, Gu Z. Gastric acid powered micromotors for combined-drug delivery to eradiate helicobacter pylori. Applied Materials Today 2023;31:101779. [DOI: 10.1016/j.apmt.2023.101779] [Reference Citation Analysis]
|
| 2 |
Jain D, Sharma G, Kumar A. Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs). Expert Opin Drug Saf 2023;:1-12. [PMID: 36888736 DOI: 10.1080/14740338.2023.2189698] [Reference Citation Analysis]
|
| 3 |
Sathe M, Moshiree B, Aliaj E, Lee M, Hudson J, Gifford A, Attel S, Gamel B, Freedman SD, Schwarzenberg SJ, Freeman AJ. Need to study simplification of gastrointestinal medication regimen in cystic fibrosis in the era of highly effective modulators. Pediatr Pulmonol 2023;58:811-8. [PMID: 36448312 DOI: 10.1002/ppul.26257] [Reference Citation Analysis]
|
| 4 |
Ito T, Ramos-Alvarez I, Jensen RT. Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES. Cancers (Basel) 2023;15. [PMID: 36900170 DOI: 10.3390/cancers15051377] [Reference Citation Analysis]
|
| 5 |
Horváth IL, Bunduc S, Hankó B, Kleiner D, Demcsák A, Szabó B, Hegyi P, Csupor D. No evidence for the benefit of PPIs in the treatment of acute pancreatitis: a systematic review and meta-analysis. Sci Rep 2023;13:2791. [PMID: 36797320 DOI: 10.1038/s41598-023-29939-5] [Reference Citation Analysis]
|
| 6 |
Edizer DT, Akcali Z, Leblebici A, Korkut SÖ, Ellidokuz E. A dual role of proton pump inhibition on cancer: a critical review. Turkish Journal of Biochemistry 2023;0. [DOI: 10.1515/tjb-2021-0296] [Reference Citation Analysis]
|
| 7 |
He XJ, Wang XL, Sun DJ, Huang XY, Liu G, Li DZ, Lin HL, Zeng XP, Li DL, Wang W. The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study. Therap Adv Gastroenterol 2023;16:17562848221147763. [PMID: 36742013 DOI: 10.1177/17562848221147763] [Reference Citation Analysis]
|
| 8 |
Russo M, Rodriguez-Castro KI, Franceschi M, Ferronato A, Panozzo MP, Brozzi L, Di Mario F, Crafa P, Brandimarte G, Tursi A. Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers. Int J Mol Sci 2023;24. [PMID: 36768710 DOI: 10.3390/ijms24032378] [Reference Citation Analysis]
|
| 9 |
Setyopranoto I, Wijayanti PM, Utami. Stroke Prevention with Anticoagulant in Cardiovascular Problem: Focus in Atrial Fibrillation. Proceedings of the 3rd International Conference on Cardiovascular Diseases (ICCvD 2021) 2023. [DOI: 10.2991/978-94-6463-048-0_32] [Reference Citation Analysis]
|
| 10 |
Koyani H, Vora N, Kalathia M, Patel N, Shah S. Drug Utilization Study of Gastroprotective Agents in Medicine and Surgery Wards of a Tertiary Care Teaching Hospital. Cureus 2023;15:e33739. [PMID: 36793848 DOI: 10.7759/cureus.33739] [Reference Citation Analysis]
|
| 11 |
Onwuzo S, Boustany A, Khaled Abou Zeid H, Hitawala A, Almomani A, Onwuzo C, Lawrence F, Mascarenhas Monteiro J, Ndubueze C, Asaad I. Prevalence and Risk Factors Associated With Inflammatory Bowel Disease in Patients Using Proton-Pump Inhibitors: A Population-Based Study. Cureus 2023;15:e34088. [PMID: 36843811 DOI: 10.7759/cureus.34088] [Reference Citation Analysis]
|
| 12 |
Gendre P, Mocquard J, Artarit P, Chaslerie A, Caillet P, Huon JF. (De)Prescribing of proton pump inhibitors: what has changed in recent years? an observational regional study from the French health insurance database. BMC Prim Care 2022;23:341. [PMID: 36582006 DOI: 10.1186/s12875-022-01941-2] [Reference Citation Analysis]
|
| 13 |
Bhardwaj S, Garvin S, Kuehl S, Van Epps J, Dunkerson F, Lehmann M, Gruber S, Kieser M, Zhao Q, Portillo E. Incorporation of Student Pharmacists into a Proton Pump Inhibitor Deprescribing Telehealth Program for Rural Veterans. Innov Pharm 2022;13. [PMID: 36627915 DOI: 10.24926/iip.v13i3.4500] [Reference Citation Analysis]
|
| 14 |
Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:2217-28. [PMID: 36181401 DOI: 10.1111/jgh.16017] [Reference Citation Analysis]
|
| 15 |
Anna Vermeulen Windsant-van den Tweel AM, Derijks HJ, Gadiot NP, Keijsers CJ. Proton Pump Inhibitors and Hypomagnesemia in Older Inpatients: An Observational Study. sr care pharm 2022;37:623-630. [DOI: 10.4140/tcp.n.2022.623] [Reference Citation Analysis]
|
| 16 |
Thompson W. Many People Take Proton Pump Inhibitor Unnecessarily: Reflecting On Why to Consider Deprescribing. sr care pharm 2022;37:600-602. [DOI: 10.4140/tcp.n.2022.600] [Reference Citation Analysis]
|
| 17 |
Dipasquale V, Cicala G, Laganà F, Cutroneo P, Trimarchi G, Spina E, Romano C. Spontaneous reporting of adverse reactions related to proton pump inhibitors. Dig Liver Dis 2022:S1590-8658(22)00780-0. [PMID: 36404233 DOI: 10.1016/j.dld.2022.10.024] [Reference Citation Analysis]
|
| 18 |
Sneh-Arbib O, Ben-Shitrit S, Weisman YL, Koshnir S, Levi Z, Calivarysky B. Using an algorithm to assess the rate and trend over time of inappropriate proton pump inhibitors prescription upon hospital discharge. Dig Liver Dis 2022:S1590-8658(22)00751-4. [PMID: 36400665 DOI: 10.1016/j.dld.2022.10.018] [Reference Citation Analysis]
|
| 19 |
Zhang ML, Fan YX, Meng R, Cai WK, Yin SJ, Zhou T, Huang YH, Wang P, Jiang FF, Yang M, He GH. Proton Pump Inhibitors and Cancer Risk: An Umbrella Review and Meta-analysis of Observational Studies. Am J Clin Oncol 2022;45:475-85. [PMID: 36255347 DOI: 10.1097/COC.0000000000000949] [Reference Citation Analysis]
|
| 20 |
Ma Y, Li S, Yang H, Zhang Y, Li H, Zhou L, Lin J, Chen Y, Hou Y, Zhang X, Liu T, Zhou X, Wang Y. Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults. Atherosclerosis 2022;358:47-54. [PMID: 36113328 DOI: 10.1016/j.atherosclerosis.2022.09.001] [Reference Citation Analysis]
|
| 21 |
Tarabay RB, Osman MH, Aridi RS, Hlais SA, Beshara RY, Lakkis NA. The effect of a patient informative leaflet on chronic use of proton pump inhibitors in a primary care center: a randomized control trial. Hosp Pract (1995) 2022;:1-8. [PMID: 35993151 DOI: 10.1080/21548331.2022.2114743] [Reference Citation Analysis]
|
| 22 |
Romano C, Scarpignato C. Pharmacologic treatment of GERD in adolescents: Is esophageal mucosal protection an option? Therap Adv Gastroenterol 2022;15:17562848221115319. [PMID: 36004307 DOI: 10.1177/17562848221115319] [Reference Citation Analysis]
|
| 23 |
Wilks A, Panahi L, Udeani G, Surani S. Review of Gastroesophageal Reflux Pharmacotherapy Management. Gastroesophageal Reflux Disease - A Growing Concern [Working Title] 2022. [DOI: 10.5772/intechopen.106338] [Reference Citation Analysis]
|
| 24 |
Ghoshal UC, Blaachandran A, Rai S, Misra A. Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease. Indian J Gastroenterol 2022;41:405-14. [PMID: 35771390 DOI: 10.1007/s12664-022-01270-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Dilaghi E, Bellisario M, Esposito G, Carabotti M, Annibale B, Lahner E. The Impact of Proton Pump Inhibitors on the Development of Gastric Neoplastic Lesions in Patients With Autoimmune Atrophic Gastritis. Front Immunol 2022;13:910077. [DOI: 10.3389/fimmu.2022.910077] [Reference Citation Analysis]
|
| 26 |
Aljahdli ES, Mokhtar AM, Aljehani SA, Hamdi RM, Alsubhi BH, Aljuhani KF, Saleh KA, Alzoriri AD, Alghamdi WS. Assessment of Awareness and Knowledge of Proton Pump Inhibitors Among the General Population in Saudi Arabia. Cureus 2022. [DOI: 10.7759/cureus.27149] [Reference Citation Analysis]
|
| 27 |
Jeridi D, Pellat A, Ginestet C, Assaf A, Hallit R, Corre F, Coriat R. The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis. J Clin Med 2022;11. [PMID: 35887860 DOI: 10.3390/jcm11144096] [Reference Citation Analysis]
|
| 28 |
Bodnarova T, Hall E, Duplan F. Prescribing habits for the use of omeprazole as a gastroprotectant in dogs in a veterinary teaching hospital. J Small Anim Pract 2022. [PMID: 35840131 DOI: 10.1111/jsap.13531] [Reference Citation Analysis]
|
| 29 |
Wakai E, Ikemura K, Mizuno T, Takeuchi K, Tamaru S, Okuda M, Nishimura Y. Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity. Front Pharmacol 2022;13:896760. [DOI: 10.3389/fphar.2022.896760] [Reference Citation Analysis]
|
| 30 |
Ben Ghezala I, Luu M, Bardou M. An update on drug-drug interactions associated with proton pump inhibitors. Expert Opin Drug Metab Toxicol 2022. [PMID: 35787720 DOI: 10.1080/17425255.2022.2098107] [Reference Citation Analysis]
|
| 31 |
Yailian A, Huet E, Charpiat B, Conort O, Juste M, Roubille R, Bourdelin M, Gravoulet J, Mongaret C, Vermorel C, Bedouch P, Janoly-duménil A, Jiang L. Characteristics of Pharmacists’ Interventions Related to Proton-Pump Inhibitors in French Hospitals: An Observational Study. International Journal of Clinical Practice 2022;2022:1-9. [DOI: 10.1155/2022/9619699] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 32 |
Turshudzhyan A, Samuel S, Tawfik A, Tadros M. Rebuilding trust in proton pump inhibitor therapy. World J Gastroenterol 2022; 28(24): 2667-2679 [DOI: 10.3748/wjg.v28.i24.2667] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 33 |
Gao J, Ma S, Xu S, Chen M, Bukhari I. The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis. Disease Markers 2022;2022:1-9. [DOI: 10.1155/2022/4093595] [Reference Citation Analysis]
|
| 34 |
Choi HG, Kong IG. The association between chronic rhinosinusitis and proton pump inhibitor use: a nested case-control study using a health screening cohort. Sci Rep 2022;12:9554. [PMID: 35689002 DOI: 10.1038/s41598-022-13271-5] [Reference Citation Analysis]
|
| 35 |
Hungin APS, Scarpignato C, Keefer L, Corsetti M, Anastasiou F, Muris JWM, Mendive JM, Kahrilas PJ. Review article: rethinking the "ladder" approach to reflux-like symptom management in the era of PPI "resistance" - a multidisciplinary perspective. Aliment Pharmacol Ther 2022;55:1492-500. [PMID: 35460095 DOI: 10.1111/apt.16930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
Oldenburger E, Brown S, Willmann J, van der Velden JM, Spałek M, van der Linden YM, Kazmierska J, Menten J, Andratschke N, Hoskin P. ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiotherapy and Oncology 2022. [DOI: 10.1016/j.radonc.2022.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 37 |
Chen S, Liu D, Chen H, Liao A, Li F, Liu C, Li X, Li S, Zhang Y, Wang Y, Xia M, Guo Q, Miao X, Wen Z, Xu M, Yin H, Chen H, Chen M, Xiao Y. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther 2022;55:1524-33. [PMID: 35505467 DOI: 10.1111/apt.16959] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 38 |
Sri Rethinavel H, Selvaraj DB, Balakrishnan SJ, Vergil Andrews JF, Joseph JHM, Kandasamy M. Omeprazole treatment manifests anxiolytic effects in a cysteamine hydrochloride induced mouse model of gastrointestinal disorder. Heliyon 2022;8:e09787. [DOI: 10.1016/j.heliyon.2022.e09787] [Reference Citation Analysis]
|
| 39 |
Savarino V, Antonioli L, Fornai M, Marabotto E, Demarzo MG, Zingone F, Ghisa M, Barberio B, Zentilin P, Ribolsi M, Savarino E. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 2022;16:401-10. [PMID: 34550866 DOI: 10.1080/17474124.2021.1984878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Kherad O, Bottequin E, Steiner D, Alibert A, Eurin R, Bothorel H. Implementing a Multifaceted Intervention among Internal Medicine Residents with Audit and Educative Data Feedback Significantly Reduces Low-Value Care in Hospitalized Patients. J Clin Med 2022;11:2435. [PMID: 35566562 DOI: 10.3390/jcm11092435] [Reference Citation Analysis]
|
| 41 |
Ardoino I, Casula M, Molari G, Mucherino S, Orlando V, Menditto E, Franchi C. Prescription Appropriateness of Drugs for Peptic Ulcer and Gastro-Esophageal Reflux Disease: Baseline Assessment in the LAPTOP-PPI Cluster Randomized Trial. Front Pharmacol 2022;13:803809. [PMID: 35418868 DOI: 10.3389/fphar.2022.803809] [Reference Citation Analysis]
|
| 42 |
Bae S, Kwon J, Lee SB, Jang IJ, Yu KS, Lee S. Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole. Drug Des Devel Ther 2021;15:5099-108. [PMID: 34992346 DOI: 10.2147/DDDT.S341271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 43 |
Arnoux A, Bailhache M, Tetard C, Rebouissoux L, Clouzeau H, Lamireau T, Enaud R. Proton pump inhibitors are still overprescribed for hospitalized children. Arch Pediatr 2022:S0929-693X(22)00072-0. [PMID: 35304031 DOI: 10.1016/j.arcped.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Lu B, Yue P, Shao Q, Mao L, Qiao H. Fertility and early embryonic development toxicity and toxicokinetic study of KFP‐H008 in Sprague–Dawley rats. Birth Defects Research. [DOI: 10.1002/bdr2.2002] [Reference Citation Analysis]
|
| 45 |
Al-Marhabi A, Hashem A, Zuberi BF, Onyekwere C, Lodhi I, Mounir M, Alkhowaiter S, Al Awadhi S, Naidoo VG, Hamada Y. The views of African and Middle Eastern Gastroenterologists on the management of mild-to-moderate, non-erosive gastro-esophageal reflux disease (GERD). Expert Rev Gastroenterol Hepatol 2022;16:217-33. [PMID: 35184616 DOI: 10.1080/17474124.2022.2043744] [Reference Citation Analysis]
|
| 46 |
Saven H, Zhong L, McFarlane IM. Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines. Cureus 2022;14:e21885. [PMID: 35273851 DOI: 10.7759/cureus.21885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 47 |
Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N, Kitasako Y, Iijima K, Koike T, Omura N, Nomura T, Kawamura O, Ohara S, Ozawa S, Kinoshita Y, Mochida S, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol 2022;57:267-85. [PMID: 35226174 DOI: 10.1007/s00535-022-01861-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 48 |
Scarpignato C. Acid-Lowering Drugs for the Treatment of Gastro-esophageal Reflux Disease. Gastroesophageal Reflux in Children 2022. [DOI: 10.1007/978-3-030-99067-1_22] [Reference Citation Analysis]
|
| 49 |
Zhang Q, Ding Q, Yan S, Yue Q. Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase. Front Pharmacol 2021;12. [DOI: 10.3389/fphar.2021.769251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 50 |
Sun S, Ye W, Zhao R, Hu J, Zhang X, Yang M, Zhao H, Sheng J. Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study. Front Med (Lausanne) 2021;8:763370. [PMID: 34859015 DOI: 10.3389/fmed.2021.763370] [Reference Citation Analysis]
|
| 51 |
Lazaridis LD, Rizos E, Bounou L, Theodorou-Kanakari A, Kalousios S, Mavroeidi EA, Roma M, Chatzidakis A, Vlachonicolou G, Miltiadou K, Gkolfakis P, Tziatzios G, Triantafyllou K. An educational intervention to optimize use of proton pump inhibitors in a Greek university hospital. Ann Gastroenterol 2021;34:781-7. [PMID: 34815643 DOI: 10.20524/aog.2021.0654] [Reference Citation Analysis]
|
| 52 |
Zullo A, Soncini M, Bucci C, Marmo R; Gruppo Italiano per lo Studio dell'Emorragia Digestiva (GISED) (Appendix). Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: A prospective, multicenter cohort study. J Gastroenterol Hepatol 2021;36:3219-23. [PMID: 34189770 DOI: 10.1111/jgh.15601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 53 |
S. M. J AL-Hadrawy, Z. S Mahdi AL-Turfi. Effects of the Long-term Treatment of Proton Pump Inhibitors on the Function of Kidney and Liver in Laboratory Female Rats . Arch Razi Inst 2021;76. [PMID: 35096333 DOI: 10.22092/ari.2021.355947.1745] [Reference Citation Analysis]
|
| 54 |
Russell P, Hewage U, McDonald C, Thompson C, Woodman R, A Mangoni A. Prospective cohort study of nonspecific deprescribing in older medical inpatients being discharged to a nursing home. Ther Adv Drug Saf 2021;12:20420986211052344. [PMID: 34707803 DOI: 10.1177/20420986211052344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 55 |
Sim W, Jain SR, Lim WH, Chin YH, Ng CH, Syn N, Goh KS, Soo R, Wang L, Goh BC. Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res 2021;10:3567-81. [PMID: 34584857 DOI: 10.21037/tlcr-21-378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 56 |
Goncuoglu C, Guven GS, Sener B, Demirkan K. Effect of gastric acid suppression on Clostridioides difficile-induced diarrhea and appropriateness of gastric acid suppressors in hospitalized patients: A matched case-control study. Arab J Gastroenterol 2021;22:292-6. [PMID: 34531136 DOI: 10.1016/j.ajg.2021.06.003] [Reference Citation Analysis]
|
| 57 |
da Rosa TF, Foletto VS, Serafin MB, Bottega A, Hörner R. Anti-infective properties of proton pump inhibitors: perspectives. Int Microbiol 2021. [PMID: 34476634 DOI: 10.1007/s10123-021-00203-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 58 |
Pironi L, Raschi E, Sasdelli AS. The safety of available treatment options for short bowel syndrome and unmet needs. Expert Opin Drug Saf 2021;:1-13. [PMID: 34105428 DOI: 10.1080/14740338.2021.1940947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 59 |
Ni X, Lin M, Li J, Zeng L, Li W, Huang L, Li D, Zhang L. Development of an evaluation indicator system for the rational use of proton pump inhibitors in pediatric intensive care units: An application of Delphi method. Medicine (Baltimore) 2021;100:e26327. [PMID: 34128875 DOI: 10.1097/MD.0000000000026327] [Reference Citation Analysis]
|
| 60 |
Hu J, Liu R, Yu X, Li Z, Liu X, Hao Y, Zhu N, Kang J, Li Y. Protective Effects of Small-Molecule Oligopeptides Isolated from Tilapia Fish Scale on Ethanol-Induced Gastroduodenal Injury in Rats. Nutrients 2021;13:2078. [PMID: 34204516 DOI: 10.3390/nu13062078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 61 |
Jagdish BR, Kilgore WR 3rd. The Relationship Between Functional Dyspepsia, PPI Therapy, and the Gastric Microbiome. Kans J Med 2021;14:136-40. [PMID: 34084274 DOI: 10.17161/kjm.vol1414831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 62 |
Sloan JA, Katz PO. Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between. Foregut 2021;1:145-151. [DOI: 10.1177/26345161211021766] [Reference Citation Analysis]
|
| 63 |
Swain LK. Narrative review of the role of inflammation in gastroesophageal reflux disease. Can food allergies play a part? Lifestyle Medicine 2021;2. [DOI: 10.1002/lim2.35] [Reference Citation Analysis]
|
| 64 |
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H, Lip GYH, Deneke T, Dagres N, Boriani G, Chao TF, Choi EK, Hills MT, Santos IS, Lane DA, Atar D, Joung B, Cole OM, Field M; External reviewers:. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021:euab065. [PMID: 33895845 DOI: 10.1093/europace/euab065] [Cited by in Crossref: 151] [Cited by in F6Publishing: 170] [Article Influence: 75.5] [Reference Citation Analysis]
|
| 65 |
Damji SS, Rabbani SA, Rao PGM, Butt AR. Proton pump inhibitor use and appropriateness analysis: a snapshot from a secondary care hospital. Journal of Pharmaceutical Health Services Research 2021;12:206-12. [DOI: 10.1093/jphsr/rmab013] [Reference Citation Analysis]
|
| 66 |
Durán C, Ciucci S, Palladini A, Ijaz UZ, Zippo AG, Sterbini FP, Masucci L, Cammarota G, Ianiro G, Spuul P, Schroeder M, Grill SW, Parsons BN, Pritchard DM, Posteraro B, Sanguinetti M, Gasbarrini G, Gasbarrini A, Cannistraci CV. Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nat Commun 2021;12:1926. [PMID: 33771992 DOI: 10.1038/s41467-021-22135-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 67 |
Gerber T, Zeller A. [Evidence-Based Indication for Proton Pump Inhibitors - a Group Practice Perspective]. Praxis (Bern 1994) 2021;110:193-200. [PMID: 33726514 DOI: 10.1024/1661-8157/a003623] [Reference Citation Analysis]
|
| 68 |
Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, Poetker DM, Soler Z, Welch KC, Wise SK, Adappa N, Alt JA, Anselmo-Lima WT, Bachert C, Baroody FM, Batra PS, Bernal-Sprekelsen M, Beswick D, Bhattacharyya N, Chandra RK, Chang EH, Chiu A, Chowdhury N, Citardi MJ, Cohen NA, Conley DB, DelGaudio J, Desrosiers M, Douglas R, Eloy JA, Fokkens WJ, Gray ST, Gudis DA, Hamilos DL, Han JK, Harvey R, Hellings P, Holbrook EH, Hopkins C, Hwang P, Javer AR, Jiang RS, Kennedy D, Kern R, Laidlaw T, Lal D, Lane A, Lee HM, Lee JT, Levy JM, Lin SY, Lund V, McMains KC, Metson R, Mullol J, Naclerio R, Oakley G, Otori N, Palmer JN, Parikh SR, Passali D, Patel Z, Peters A, Philpott C, Psaltis AJ, Ramakrishnan VR, Ramanathan M Jr, Roh HJ, Rudmik L, Sacks R, Schlosser RJ, Sedaghat AR, Senior BA, Sindwani R, Smith K, Snidvongs K, Stewart M, Suh JD, Tan BK, Turner JH, van Drunen CM, Voegels R, Wang Y, Woodworth BA, Wormald PJ, Wright ED, Yan C, Zhang L, Zhou B. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 2021;11:213-739. [PMID: 33236525 DOI: 10.1002/alr.22741] [Cited by in Crossref: 147] [Cited by in F6Publishing: 153] [Article Influence: 73.5] [Reference Citation Analysis]
|
| 69 |
Scarpignato C, Hunt RH. Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. Curr Treat Options Gastro 2021;19:94-132. [DOI: 10.1007/s11938-020-00330-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 70 |
Scarpignato C, Wang DH. Cancer Prevention in Patients with GERD and Barrett’s Esophagus—Medicine. Foregut 2021;1:50-62. [DOI: 10.1177/2634516121993676] [Reference Citation Analysis]
|
| 71 |
Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563. [PMID: 33589415 DOI: 10.1136/bmjgast-2020-000563] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 72 |
Albarqouni L, Moynihan R, Clark J, Scott AM, Duggan A, Del Mar C. Head of bed elevation to relieve gastroesophageal reflux symptoms: a systematic review. BMC Fam Pract 2021;22:24. [PMID: 33468060 DOI: 10.1186/s12875-021-01369-0] [Reference Citation Analysis]
|
| 73 |
Akutay S, Ceyhan Ö. Proton Pompa İnhibitörlerinin Kırık Oluşumuna Etkisi ve Bakıma Yansıması. Dokuz Eylül Üniversitesi Hemşirelik Fakültesi Elektronik Dergisi 2021. [DOI: 10.46483/deuhfed.736337] [Reference Citation Analysis]
|
| 74 |
Graham DY, Khalaf N. Peptic Ulcer Disease. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_63] [Reference Citation Analysis]
|
| 75 |
Triadafilopoulos G. GERD Outlook: A Gastroenterologist’s Perspective. Multidisciplinary Management of Gastroesophageal Reflux Disease 2021. [DOI: 10.1007/978-3-030-53751-7_15] [Reference Citation Analysis]
|
| 76 |
Gunturu SG, Dharmarajan TS. Drug–Nutrient Interactions. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-319-90761-1_13-1] [Reference Citation Analysis]
|
| 77 |
Jain M. Feasibility and determinants of deprescription of proton pump inhibitors in patients with typical reflux symptoms. Gastroenterol Hepatol Endosc Pract 2021;1:98. [DOI: 10.4103/ghep.ghep_25_20] [Reference Citation Analysis]
|
| 78 |
Goriacko P, Veltri KT. Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective). Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_10] [Reference Citation Analysis]
|
| 79 |
Gunturu SG, Dharmarajan TS. Drug–Nutrient Interactions. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_13] [Reference Citation Analysis]
|
| 80 |
Chen F, He X, Fang B, Wang S. Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use. Drug Des Devel Ther 2020;14:5689-98. [PMID: 33380789 DOI: 10.2147/DDDT.S279302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 81 |
Dharmarajan TS. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. J Am Med Dir Assoc 2021;22:15-22. [PMID: 33321078 DOI: 10.1016/j.jamda.2020.09.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 82 |
Cucchi D, Menon A, Feroldi FM, Boerci L, Randelli PS. The presence of gastroesophageal reflux disease increases the risk of developing postoperative shoulder stiffness after arthroscopic rotator cuff repair. J Shoulder Elbow Surg 2020;29:2505-13. [PMID: 32711105 DOI: 10.1016/j.jse.2020.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 83 |
Saiz Ladera GM, Pejenaute Labari ME, García Pascual JN. [Updating in prescription of proton pump inhibitors. What to do and what not to do]. Semergen 2021;47:267-79. [PMID: 33223372 DOI: 10.1016/j.semerg.2020.09.011] [Reference Citation Analysis]
|
| 84 |
Chen F, Jiang H, Xu J, Wang S, Meng D, Geng P, Dai D, Zhou Q, Zhou Y. In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine. Drug Des Devel Ther 2020;14:4815-24. [PMID: 33204067 DOI: 10.2147/DDDT.S276704] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 85 |
Hunt RH, East JE, Lanas A, Malfertheiner P, Satsangi J, Scarpignato C, Webb GJ. COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. Dig Dis 2021;39:119-39. [PMID: 33040064 DOI: 10.1159/000512152] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 86 |
. UEG Week 2020 Poster Presentations. United European Gastroenterol J 2020;8:144-887. [PMID: 33043826 DOI: 10.1177/2050640620927345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 87 |
Hoteit M, Mattar E, Allaw R, Abou Rached A. Epidemiological Study Assessing the Overuse of Proton Pump Inhibitors in Lebanese Population. Middle East J Dig Dis 2020;12:265-70. [PMID: 33564384 DOI: 10.34172/mejdd.2020.192] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 88 |
Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci 2020;1482:193-212. [PMID: 32935346 DOI: 10.1111/nyas.14473] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 89 |
Tansey P, Shiels P. Inappropriate prescribing of proton pump inhibitors (PPI) in patients > 65 years at a level 2 Irish hospital. Ir J Med Sci 2021;190:853-4. [PMID: 32910401 DOI: 10.1007/s11845-020-02368-3] [Reference Citation Analysis]
|
| 90 |
Scarpignato C, Sloan JA, Wang DH, Hunt RH. Gastrointestinal pharmacology: practical tips for the esophagologist. Ann N Y Acad Sci 2020;1481:90-107. [PMID: 32822080 DOI: 10.1111/nyas.14447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 91 |
Oppenheimer EE, Schmit B, Sarosi GA Jr, Thomas RM. Proton Pump Inhibitor Use After Hiatal Hernia Repair: Inhibitor of Recurrent Symptoms and Potential Revisional Surgery. J Surg Res 2020;256:570-6. [PMID: 32805579 DOI: 10.1016/j.jss.2020.07.033] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 92 |
Puchon E, Goboova M, Vano I, Fazekas T, Javorova-rihova Z, Kuzelova M. Medication-related factors associated with proton pump inhibitor prescription beyond official guidelines in older adults. Eur Geriatr Med 2020;11:1051-61. [DOI: 10.1007/s41999-020-00380-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 93 |
Thompson W, Nissen M, Haastrup P, Le JV, Lundby C, Nielsen JB, Jarbøl DE. Discussing proton pump inhibitor deprescribing: the views of Danish GPs and older patients. BMC Fam Pract 2020;21:160. [PMID: 32770959 DOI: 10.1186/s12875-020-01227-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 94 |
Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci 2020;1481:43-58. [PMID: 32761834 DOI: 10.1111/nyas.14428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 95 |
Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis 2020;52:842-52. [PMID: 32513631 DOI: 10.1016/j.dld.2020.04.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 96 |
Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, Furnari M, Marabotto E, Plaz Torres MC, Zentilin P, Savarino V. Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Dig Liver Dis 2020;52:862-8. [PMID: 32505566 DOI: 10.1016/j.dld.2020.05.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 97 |
Scarpignato C, Tolone S. Addressing long-term PPI safety. Dig Liver Dis 2020;52:853-6. [PMID: 32601032 DOI: 10.1016/j.dld.2020.05.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 98 |
Greiwe J, Cooke A, Nanda A, Epstein SZ, Wasan AN, Shepard KV 2nd, Capão-Filipe M, Nish A, Rubin M, Gregory KL, Dass K, Blessing-Moore J, Randolph C. Work Group Report: Perspectives in Diagnosis and Management of Exercise-Induced Bronchoconstriction in Athletes. J Allergy Clin Immunol Pract 2020;8:2542-55. [PMID: 32636147 DOI: 10.1016/j.jaip.2020.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 99 |
Kim TH. Proton Pump Inhibitor Long-term Prescription, Is It Safe? Korean J Helicobacter Up Gastrointest Res 2020;20:83-85. [DOI: 10.7704/kjhugr.2020.0009] [Reference Citation Analysis]
|
| 100 |
Rattanasuwan T, Khoury AP, Ebied AM. Proton Pump Inhibitors: for What and for How Long. SN Compr Clin Med 2020;2:719-726. [DOI: 10.1007/s42399-020-00268-2] [Reference Citation Analysis]
|
| 101 |
Lachaux A. Protecteurs gastriques et risque d’allergie alimentaire. Revue Française d'Allergologie 2020;60:186-187. [DOI: 10.1016/j.reval.2020.02.007] [Reference Citation Analysis]
|
| 102 |
Douwes RM, Gomes-Neto AW, Eisenga MF, Van Loon E, Schutten JC, Gans ROB, Naesens M, van den Berg E, Sprangers B, Berger SP, Navis G, Blokzijl H, Meijers B, Bakker SJL, Kuypers D. The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study. PLoS Med 2020;17:e1003140. [PMID: 32542023 DOI: 10.1371/journal.pmed.1003140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 103 |
Sasaki T, Mori S, Kishi S, Fujiwara-Tani R, Ohmori H, Nishiguchi Y, Hojo Y, Kawahara I, Nakashima C, Fujii K, Luo Y, Kuniyasu H. Effect of Proton Pump Inhibitors on Colorectal Cancer. Int J Mol Sci 2020;21:E3877. [PMID: 32485921 DOI: 10.3390/ijms21113877] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 104 |
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Tolone S, De Bortoli N, Frazzoni M, Savarino E. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol 2020;13:437-49. [PMID: 32253948 DOI: 10.1080/17512433.2020.1752664] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 105 |
Schnoll-Sussman F, Niec R, Katz PO. Proton Pump Inhibitors: The Good, Bad, and Ugly. Gastrointest Endosc Clin N Am 2020;30:239-51. [PMID: 32146944 DOI: 10.1016/j.giec.2019.12.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 106 |
Ciucci S, Durán C, Palladini A, Ijaz UZ, Sterbini FP, Masucci L, Cammarota G, Ianiro G, Spuul P, Schroeder M, Grill SW, Parsons BN, Pritchard DM, Posteraro B, Sanguinetti M, Gasbarrini G, Gasbarrini A, Cannistraci CV. Machine learning pattern recognition and differential network analysis of gastric microbiome in the presence of proton pump inhibitor treatment or Helicobacter pylori infection.. [DOI: 10.1101/2020.03.24.005587] [Reference Citation Analysis]
|
| 107 |
Daniels B, Pearson SA, Buckley NA, Bruno C, Zoega H. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. Therap Adv Gastroenterol 2020;13:1756284820913743. [PMID: 32218806 DOI: 10.1177/1756284820913743] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 108 |
Tozzi M, Sørensen CE, Magni L, Christensen NM, Bouazzi R, Buch CM, Stefanini M, Duranti C, Arcangeli A, Novak I. Proton Pump Inhibitors Reduce Pancreatic Adenocarcinoma Progression by Selectively Targeting H+, K+-ATPases in Pancreatic Cancer and Stellate Cells. Cancers (Basel) 2020;12:E640. [PMID: 32164284 DOI: 10.3390/cancers12030640] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 109 |
Franchi C, Mannucci PM, Nobili A, Ardoino I. Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. Eur J Clin Pharmacol 2020;76:459-65. [PMID: 31853593 DOI: 10.1007/s00228-019-02815-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 110 |
Leitinger E, Hui L, Grigg A. Is there a role for proton pump inhibitor prophylaxis in haematology patients? Intern Med J 2019;49:694-701. [PMID: 30719802 DOI: 10.1111/imj.14241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 111 |
Broide E, Eindor-Abarbanel A, Shirin H, Richter V, Matalon S, Leshno M. Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice. BMJ Open 2020;10:e031091. [PMID: 32051298 DOI: 10.1136/bmjopen-2019-031091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 112 |
Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology 2020;59:e1-e23. [DOI: 10.1093/rheumatology/kez672] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 25.3] [Reference Citation Analysis]
|
| 113 |
Vinke P, Wesselink E, van Orten-Luiten W, van Norren K. The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses. Int J Mol Sci 2020;21:E323. [PMID: 31947724 DOI: 10.3390/ijms21010323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 114 |
Park M, Yoo J, Lee K. Current Guidelines for Non-Steroidal Anti-Inflammatory Drugs. J Korean Orthop Assoc 2020;55:9. [DOI: 10.4055/jkoa.2020.55.1.9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 115 |
Khilnani P, Rawal N, Singha C. Gastrointestinal Issues in Critically Ill Children. Indian J Crit Care Med 2020;24:S201-4. [PMID: 33354042 DOI: 10.5005/jp-journals-10071-23637] [Reference Citation Analysis]
|
| 116 |
Goriacko P, Veltri KT. Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective). Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_10-1] [Reference Citation Analysis]
|
| 117 |
Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [PMID: 31838548 DOI: 10.1007/s00228-019-02810-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 118 |
Motter FR, Hilmer SN, Paniz VMV. Pain and Inflammation Management in Older Adults: A Brazilian Consensus of Potentially Inappropriate Medication and Their Alternative Therapies. Front Pharmacol 2019;10:1408. [PMID: 31849664 DOI: 10.3389/fphar.2019.01408] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 119 |
Walker MJ, Crews NR, El-Halabi M, Fayad NF. Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics. Gastroenterology Res 2019;12:305-11. [PMID: 31803310 DOI: 10.14740/gr1238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 120 |
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-93. [PMID: 29562325 DOI: 10.1093/eurheartj/ehy136] [Cited by in Crossref: 1188] [Cited by in F6Publishing: 1250] [Article Influence: 297.0] [Reference Citation Analysis]
|
| 121 |
Scarpignato C, Bjarnason I. Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. Curr Gastroenterol Rep 2019;21:55. [PMID: 31720893 DOI: 10.1007/s11894-019-0726-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 122 |
Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome. Int J Mol Sci 2019;20:E5128. [PMID: 31623145 DOI: 10.3390/ijms20205128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 123 |
Wang H, Shao F, Liu X, Xu W, Ou N, Qin X, Liu F, Hou X, Hu H, Jiang J. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. Br J Clin Pharmacol 2019;85:2547-58. [PMID: 31332820 DOI: 10.1111/bcp.14076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 124 |
Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, Ghoshal UC, Ahuja V, Rao GV, Devadas K, Dutta AK, Jain A, Kedia S, Dama R, Kalapala R, Alvares JF, Dadhich S, Dixit VK, Goenka MK, Goswami BD, Issar SK, Leelakrishnan V, Mallath MK, Mathew P, Mathew P, Nandwani S, Pai CG, Peter L, Prasad AVS, Singh D, Sodhi JS, Sud R, Venkataraman J, Midha V, Bapaye A, Dutta U, Jain AK, Kochhar R, Puri AS, Singh SP, Shimpi L, Sood A, Wadhwa RT. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol 2019;38:411-40. [PMID: 31802441 DOI: 10.1007/s12664-019-00979-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 125 |
Baltz AP, Gressler LE, Costantino RC, Mcpherson ML. Nonprescription Medication Use in Hospice Patients. Am J Hosp Palliat Care 2020;37:336-42. [DOI: 10.1177/1049909119876259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 126 |
M ZA, Lavu A, Ansari M, V RA, Vilakkathala R. A Cross-Sectional Study on Single-Day Use of Proton Pump Inhibitors in Tertiary Care Hospitals of South India. Hosp Pharm 2021;56:109-15. [PMID: 33790486 DOI: 10.1177/0018578719873876] [Reference Citation Analysis]
|
| 127 |
De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 128 |
Abbas MK, Zaidi ARZ, Robert CA, Thiha S, Malik BH. The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review. Cureus 2019;11:e5563. [PMID: 31523592 DOI: 10.7759/cureus.5563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 129 |
Vatcharavongvan P, Puttawanchai V. Potentially inappropriate medications among the elderly in primary care in Thailand from three different sets of criteria. Pharm Pract (Granada) 2019;17:1494. [PMID: 31592037 DOI: 10.18549/PharmPract.2019.3.1494] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 130 |
Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology 2019;70:640-9. [PMID: 30289992 DOI: 10.1002/hep.30304] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 131 |
Corsonello A, Lattanzio F. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe? Trends in Cardiovascular Medicine 2019;29:353-60. [DOI: 10.1016/j.tcm.2018.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 132 |
Savarino V, Marabotto E, Zentilin P, Savarino E. The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. Expert Rev Clin Pharmacol 2019;12:1011-2. [PMID: 31305167 DOI: 10.1080/17512433.2019.1643199] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 133 |
Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol 2019;35:344-55. [PMID: 31045597 DOI: 10.1097/MOG.0000000000000543] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 134 |
Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 98] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 135 |
Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018;19:145-58. [PMID: 29464446 DOI: 10.1007/s11154-018-9443-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 136 |
Makarchuk VV, VG Korolenko Poltava National Pedagogical University 2, Ostrogradski St., Poltava 36000, Ukraine, Pylypenko SV, Koval’ AA. Influence of Prolonged Using of Proton Pump Blockers on the Stomach and Colon Microflora in Rats. Ukr ž med bìol sportu 2019;4:278-283. [DOI: 10.26693/jmbs04.02.278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 137 |
Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and Treatment of Peptic Ulcer Disease. Am J Med 2019;132:447-56. [PMID: 30611829 DOI: 10.1016/j.amjmed.2018.12.009] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 22.5] [Reference Citation Analysis]
|
| 138 |
Jung HJ, Kim JH, Kang MH, Lee DW. Effects of Proton Pump Inhibitor for Laryngopharyngeal Reflux and Comorbid Chronic Rhinosinusitis. Korean J Otorhinolaryngol-Head Neck Surg 2019;62:165-170. [DOI: 10.3342/kjorl-hns.2018.00521] [Reference Citation Analysis]
|
| 139 |
Zullo A, Manta R, De Francesco V, Fiorini G, Hassan C, Vaira D. Diagnostic yield of upper endoscopy according to appropriateness: A systematic review. Dig Liver Dis 2019;51:335-9. [PMID: 30583999 DOI: 10.1016/j.dld.2018.11.029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 140 |
Hunt R, B Lazebnik L, C Marakhouski Y, Manuc M, Gn R, S Aye K, S Bordin D, V Bakulina N, S Iskakov B, A Khamraev A, M Stepanov Y, Ally R, Garg A. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G. Euroasian J Hepatogastroenterol 2018;8:148-60. [PMID: 30828557 DOI: 10.5005/jp-journals-10018-1281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 141 |
Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol 2019;33:327-38. [PMID: 30625254 DOI: 10.1111/fcp.12436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 142 |
Schmulson M, Frati-munari A. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. Revista de Gastroenterología de México (English Edition) 2019;84:44-51. [DOI: 10.1016/j.rgmxen.2018.05.011] [Reference Citation Analysis]
|
| 143 |
Bell R, Lipham J, Louie B, Williams V, Luketich J, Hill M, Richards W, Dunst C, Lister D, McDowell-Jacobs L, Reardon P, Woods K, Gould J, Buckley FP 3rd, Kothari S, Khaitan L, Smith CD, Park A, Smith C, Jacobsen G, Abbas G, Katz P. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. Gastrointest Endosc 2019;89:14-22.e1. [PMID: 30031018 DOI: 10.1016/j.gie.2018.07.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 144 |
Yadlapati R, Khan A. Gastroesophageal Reflux Disease. Gastrointestinal and Liver Disorders in Women’s Health 2019. [DOI: 10.1007/978-3-030-25626-5_3] [Reference Citation Analysis]
|
| 145 |
Voukelatou P, Vrettos I, Emmanouilidou G, Dodos K, Skotsimara G, Kontogeorgou D, Kalliakmanis A. Predictors of Inappropriate Proton Pump Inhibitors Use in Elderly Patients. Curr Gerontol Geriatr Res 2019;2019:7591045. [PMID: 30713553 DOI: 10.1155/2019/7591045] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 146 |
Graham DY, Khalaf N. Peptic Ulcer Disease. Geriatric Gastroenterology 2019. [DOI: 10.1007/978-3-319-90761-1_63-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 147 |
Mănuc M. Management of patients with NSAIDs-induced gastropathy – short assessments based on the International Consensus on Guiding Recommendations on NSAIDs-induced Gastropathy. Medic ro 2019;5:10. [DOI: 10.26416/med.131.3.2019.2577] [Reference Citation Analysis]
|
| 148 |
Poly T, Islam M, Yang H, Wu C, Li Y. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 2019;30:103-14. [DOI: 10.1007/s00198-018-4788-y] [Cited by in Crossref: 69] [Cited by in F6Publishing: 50] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 149 |
Stasi E, Michielan A, Morreale GC, Tozzi A, Venezia L, Bortoluzzi F, Triossi O, Soncini M, Leandro G, Milazzo G, Anderloni A. Five common errors to avoid in clinical practice: the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Choosing Wisely Campaign. Intern Emerg Med 2019;14:301-8. [PMID: 30499071 DOI: 10.1007/s11739-018-1992-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 150 |
Svanström H, Lund M, Melbye M, Pasternak B. Use of Proton Pump Inhibitors and the Risk of Acute Kidney Injury Among Patients with Rheumatoid Arthritis: Cohort Study. Drug Saf 2018;41:817-26. [PMID: 29603109 DOI: 10.1007/s40264-018-0663-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 151 |
Paliwal P, Kumar AS, Tripathi H, Singh S, Patne SC, Krishnamurthy S. Pharmacological application of barium containing bioactive glass in gastro-duodenal ulcers. Materials Science and Engineering: C 2018;92:424-34. [DOI: 10.1016/j.msec.2018.06.068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 152 |
Lahner E, Carabotti M, Esposito G, Hassan C, Zullo A, Annibale B. Occurrence and predictors of metaplastic atrophic gastritis in a nation-wide consecutive endoscopic population presenting with upper gastrointestinal symptoms. Eur J Gastroenterol Hepatol 2018;30:1291-6. [PMID: 30161028 DOI: 10.1097/MEG.0000000000001246] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 153 |
Hunt RH, Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastro 2018;16:570-90. [DOI: 10.1007/s11938-018-0206-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 154 |
Spechler SJ. Proton Pump Inhibitors: What the Internist Needs to Know. Med Clin North Am 2019;103:1-14. [PMID: 30466666 DOI: 10.1016/j.mcna.2018.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 155 |
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol 2018;11:1123-34. [PMID: 30295105 DOI: 10.1080/17512433.2018.1531703] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 156 |
Lachaux A, Caron N. Les inhibiteurs de la pompe à proton (IPP), inducteurs et cofacteurs d’allergie. Revue Française d'Allergologie 2018;58:450-451. [DOI: 10.1016/j.reval.2018.03.008] [Reference Citation Analysis]
|
| 157 |
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. The appropriate use of proton-pump inhibitors. Minerva Med 2018;109. [DOI: 10.23736/s0026-4806.18.05705-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 158 |
Savarino V, Tosetti C, Benedetto E, Compare D, Nardone G. Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) - Study section "Digestive Diseases in Primary Care". Dig Liver Dis 2018;50:894-902. [PMID: 30093304 DOI: 10.1016/j.dld.2018.07.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 159 |
Shao YJ, Chan TS, Tsai K, Wu SY. Association between proton pump inhibitors and the risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:460-8. [PMID: 29897132 DOI: 10.1111/apt.14835] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 160 |
Radhamanalan R, Alagumuthu M, Nagaraju N. Synthesis and drug efficacy validations of racemic-substituted benzimidazoles as antiulcer/antigastric secretion agents. Future Medicinal Chemistry 2018;10:1805-20. [DOI: 10.4155/fmc-2017-0214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 161 |
Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety 2018;17:785-94. [DOI: 10.1080/14740338.2018.1497155] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 162 |
Morschel CF, Mafra D, Eduardo JCC. The relationship between proton pump inhibitors and renal disease. J Bras Nefrol 2018;40:301-6. [PMID: 30010692 DOI: 10.1590/2175-8239-jbn-2018-0021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 163 |
Steinbach EC, Hernandez M, Dellon ES. Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. J Allergy Clin Immunol Pract 2018;6:1483-95. [PMID: 30201096 DOI: 10.1016/j.jaip.2018.06.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 164 |
Gatta L, Scarpignato C. Editorial: Helicobacter pylori resistance and sequential therapy-authors' reply. Aliment Pharmacol Ther 2018;48:96-7. [PMID: 29882988 DOI: 10.1111/apt.14676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 165 |
Pesek RD, Gupta SK. Emerging drugs for eosinophilic esophagitis. Expert Opin Emerg Drugs. 2018;23:173-183. [PMID: 29848130 DOI: 10.1080/14728214.2018.1483335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 166 |
Liatsos C, Rokkas T. The Effect of Chronic Use of Proton Pump Inhibitors on Gastric Cancer: Should We Be Aware of It? Dig Dis 2018;36:395-6. [PMID: 29874647 DOI: 10.1159/000489629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 167 |
Graham DY, Tansel A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol 2018;16:800-808.e7. [PMID: 28964908 DOI: 10.1016/j.cgh.2017.09.033] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 168 |
Fiorini G, Zullo A, Saracino IM, Gatta L, Pavoni M, Vaira D. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. Eur J Gastroenterol Hepatol 2018;30:621-5. [PMID: 29481383 DOI: 10.1097/MEG.0000000000001102] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 169 |
Paradkar S. Reported Adverse Drug Reactions During the Use of Corticosteroids in a Tertiary Care Hospital. Ther Innov Regul Sci 2019;53:128-31. [PMID: 29759019 DOI: 10.1177/2168479018776262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 170 |
Gyawali CP, Azagury DE, Chan WW, Chandramohan SM, Clarke JO, Bortoli N, Figueredo E, Fox M, Jodorkovsky D, Lazarescu A, Malfertheiner P, Martinek J, Murayama KM, Penagini R, Savarino E, Shetler KP, Stein E, Tatum RP, Wu J. Nonerosive reflux disease: clinical concepts. Ann N Y Acad Sci 2018;1434:290-303. [DOI: 10.1111/nyas.13845] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 171 |
Colombo F, Nunnari P, Ceccarelli G, Romano AV, Barbieri P, Scaglione F. Measures of Drug Prescribing at Care Transitions in an Internal Medicine Unit. J Clin Pharmacol 2018;58:1171-83. [PMID: 29723431 DOI: 10.1002/jcph.1123] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 172 |
Gamelas V, Salvado V, Dias L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol 2019;26:114-20. [PMID: 30976616 DOI: 10.1159/000488506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 173 |
Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [PMID: 29536561 DOI: 10.1111/apt.14597] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 174 |
Schmulson MJ, Frati-Munari AC. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. Rev Gastroenterol Mex. 2019;84:44-51. [PMID: 29678362 DOI: 10.1016/j.rgmx.2018.02.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 175 |
Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 176 |
Qorraj-Bytyqi H, Hoxha R, Sadiku S, Bajraktari IH, Sopjani M, Thaçi K, Thaçi S, Bahtiri E. Proton Pump Inhibitors Intake and Iron and Vitamin B12 Status: A Prospective Comparative Study with a Follow up of 12 Months. Open Access Maced J Med Sci 2018;6:442-6. [PMID: 29610598 DOI: 10.3889/oamjms.2018.142] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 177 |
Franceschelli S, Gatta DMP, Pesce M, Ferrone A, Di Martino G, Di Nicola M, De Lutiis MA, Vitacolonna E, Patruno A, Grilli A, Felaco M, Speranza L. Modulation of the oxidative plasmatic state in gastroesophageal reflux disease with the addition of rich water molecular hydrogen: A new biological vision. J Cell Mol Med 2018;22:2750-9. [PMID: 29512923 DOI: 10.1111/jcmm.13569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 178 |
Boucherie Q, Rouby F, Frankel D, Roll P, Micallef J. Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. Therapie 2018;73:385-8. [PMID: 29778306 DOI: 10.1016/j.therap.2018.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 179 |
Xavier S, Magalhães J, Cotter J. Proton Pump Inhibitors: Are They a Real Threat to the Patient? GE Port J Gastroenterol 2018;25:243-52. [PMID: 30320163 DOI: 10.1159/000487154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 180 |
Avraham O, Biglow M. Implementation of Proton Pump Inhibitor Deprescription Protocol in Geriatric Residents. Ann Pharmacother 2018;52:747-53. [PMID: 29473423 DOI: 10.1177/1060028018759747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 181 |
Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J Pain Res. 2018;11:361-374. [PMID: 29491719 DOI: 10.2147/jpr.s156938] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 182 |
Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 183 |
Ng HS, Koczwara B, Roder DM, Niyonsenga T, Vitry AI. Comorbidities in Australian women with hormone‐dependent breast cancer: a population‐based analysis. Medical Journal of Australia 2018;208:24-8. [DOI: 10.5694/mja17.00006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 184 |
Sivasubramaniam R, Harvey RJ. How to Assess, Control, and Manage Uncontrolled CRS/Nasal Polyp Patients. Curr Allergy Asthma Rep 2017;17:58. [PMID: 28770480 DOI: 10.1007/s11882-017-0728-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 185 |
Thaker AM, Raman Muthusamy V. Non-operative Treatment of Gastroesophageal Reflux Disease. A Mastery Approach to Complex Esophageal Diseases 2018. [DOI: 10.1007/978-3-319-75795-7_1] [Reference Citation Analysis]
|
| 186 |
Scarpignato C, Gatta L. Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. Reflux Aspiration and Lung Disease 2018. [DOI: 10.1007/978-3-319-90525-9_23] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 187 |
Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology 2018;154:302-18. [PMID: 28827081 DOI: 10.1053/j.gastro.2017.07.049] [Cited by in Crossref: 164] [Cited by in F6Publishing: 165] [Article Influence: 32.8] [Reference Citation Analysis]
|
| 188 |
Cates DJ, Randall DR. Evidence-Based Practice. Evidence-Based Clinical Practice in Otolaryngology 2018. [DOI: 10.1016/b978-0-323-54460-3.00011-7] [Reference Citation Analysis]
|
| 189 |
Wahking RA, Steele RL, Hanners RE, Lockwood SM, Davis KW. Outcomes From a Pharmacist - led Proton Pump Inhibitor Stewardship Program at a Single Institution. Hosp Pharm 2018;53:59-67. [PMID: 29434389 DOI: 10.1177/0018578717747192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 190 |
Cooper CA, Urso PP. Gastroesophageal Reflux in the Intensive Care Unit Patient. Crit Care Nurs Clin North Am 2018;30:123-35. [PMID: 29413207 DOI: 10.1016/j.cnc.2017.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 191 |
Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 144] [Cited by in F6Publishing: 136] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 192 |
Zullo A, De Francesco V, Vaira D. Is Double-Dose Esomeprazole With Bismuth Really Safe? Am J Gastroenterol 2017;112:1894-5. [PMID: 29215618 DOI: 10.1038/ajg.2017.386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 193 |
Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;11:CD011194. [PMID: 29161458 DOI: 10.1002/14651858.CD011194.pub3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 194 |
Eltahir HM, Nazmy MH. Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers. Biomed Pharmacother 2018;97:1356-65. [PMID: 29156525 DOI: 10.1016/j.biopha.2017.11.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 195 |
Wilson JM, McGowan EC. Diagnosis and Management of Eosinophilic Esophagitis. Immunol Allergy Clin North Am 2018;38:125-39. [PMID: 29132668 DOI: 10.1016/j.iac.2017.09.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 196 |
Alkhathami AM, Alzahrani AA, Alzhrani MA, Alsuwat OB, Mahfouz MEM. Risk Factors for Gastroesophageal Reflux Disease in Saudi Arabia. Gastroenterology Res 2017;10:294-300. [PMID: 29118870 DOI: 10.14740/gr906w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 197 |
Anzić S, Turkalj M, Župan A, Labor M, Plavec D, Baudoin T. Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double-blind, placebo-controlled trial. Clin Otolaryngol 2018;43:496-501. [DOI: 10.1111/coa.13005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 198 |
Kahrilas P, Yadlapati R, Roman S. Emerging dilemmas in the diagnosis and management of gastroesophageal reflux disease. F1000Res 2017;6:1748. [PMID: 29034088 DOI: 10.12688/f1000research.11918.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 199 |
Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017; 23(35): 6500-6515 [PMID: 29085200 DOI: 10.3748/wjg.v23.i35.6500] [Cited by in CrossRef: 140] [Cited by in F6Publishing: 144] [Article Influence: 23.3] [Reference Citation Analysis]
|
| 200 |
Naunton M, Peterson GM, Deeks LS, Young H, Kosari S. We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther 2018;43:65-72. [PMID: 28895169 DOI: 10.1111/jcpt.12613] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 201 |
Tosetti C, Nanni I. Use of proton pump inhibitors in general practice. World J Gastrointest Pharmacol Ther 2017; 8(3): 180-185 [PMID: 28828196 DOI: 10.4292/wjgpt.v8.i3.180] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 202 |
Gyawali CP. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0586-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 203 |
Yadlapati R, Kahrilas PJ. The "dangers" of chronic proton pump inhibitor use. J Allergy Clin Immunol 2018;141:79-81. [PMID: 28729001 DOI: 10.1016/j.jaci.2017.06.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 204 |
Shin MR, An HJ, Seo BI, Roh SS. Anti-apoptotic effect of banhasasim-tang on chronic acid reflux esophagitis. World J Gastroenterol 2017; 23(25): 4644-4653 [PMID: 28740353 DOI: 10.3748/wjg.v23.i25.4644] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 205 |
Davis KW, Hanners RE, Lockwood SM. Implementation of a proton pump inhibitor stewardship program. American Journal of Health-System Pharmacy 2017;74:932-7. [DOI: 10.2146/ajhp160670] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 206 |
Tommasi S, Elliot DJ, Hulin JA, Lewis BC, McEvoy M, Mangoni AA. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Sci Rep 2017;7:2871. [PMID: 28588208 DOI: 10.1038/s41598-017-03069-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 207 |
Juntunen H, Taipale H, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S, Tiihonen M. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease. Eur J Clin Pharmacol 2017;73:1149-58. [PMID: 28577224 DOI: 10.1007/s00228-017-2273-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 208 |
Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, Katelaris P, Tutuian RI, Castell DO. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs 2017;77:547-61. [PMID: 28233274 DOI: 10.1007/s40265-017-0712-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 209 |
Mcconachie S, Wilhelm S. Gastroesophageal Reflux Disease. PharmacotherapyFirst: A Multimedia Learning Resource 2017. [DOI: 10.21019/pharmacotherapyfirst.gerd_overview] [Reference Citation Analysis]
|
| 210 |
Sharma R, Roy A, Ramos C, Rosenberg R, Garcia-Carrasquillo R, Lebwohl B. Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation. Therap Adv Gastroenterol 2017;10:387-96. [PMID: 28507597 DOI: 10.1177/1756283X17694807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 211 |
Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017;96:e6723. [PMID: 28445288 DOI: 10.1097/MD.0000000000006723] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 212 |
Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;3:CD011194. [PMID: 28271513 DOI: 10.1002/14651858.CD011194.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 213 |
Shin MR, Seo BI, Son CG, Roh SS, An HJ. Banhasasim-Tang Treatment Reduces the Severity of Esophageal Mucosal Ulcer on Chronic Acid Reflux Esophagitis in Rats. Biomed Res Int 2017;2017:7157212. [PMID: 28349065 DOI: 10.1155/2017/7157212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 214 |
Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med 2017;15:36. [PMID: 28219434 DOI: 10.1186/s12916-017-0804-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 215 |
Aronson JK. Inhibiting the proton pump: mechanisms, benefits, harms, and questions. BMC Med 2016;14:172. [PMID: 27825384 DOI: 10.1186/s12916-016-0724-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
